Tesofensine
Chemical compound
Tesofensine (NS2330) is a serotonin–norepinephrine–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity. Tesofensine was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014.
Nº Q7705544 ★
Common · Knowledge
Tesofensine
Chemical compound
Tesofensine (NS2330) is a serotonin–norepinephrine–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity. Tesofensine was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014.
Last price
—
Floor price
—
7-day median
—
30-day sales
0
30-day range
—
In circulation
0
Price history
median
low – high
sales
No sales in this period
Show table
| Date | median | Low | High | sales |
|---|
Sales history
- Last sale
- —
- 30-day average
- —
- 30-day low
- —
- 30-day high
- —
- Sales 7d
- 0
- Sales 30d
- 0
No sales yet.
Anonymous sales: no buyer or seller shown. Figures count player-to-player sales only.
From Wikipedia
Tesofensine (NS2330) is a serotonin–norepinephrine–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity. Tesofensine was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014. As of 2019, tesofensine has been discontinued for the treatment of Alzheimer's and Parkinson's disease but is in phase III clinical trial for obesity.
Text: Wikipédia, CC BY-SA 4.0. · Image: Cacycle (Public domain) ·
Related cards
Tetrabenazine
Chemical compound
Nº Q413050 ★
Solriamfetol
A medicine for alertness
Nº Q39059979 ★★
Dapoxetine
Chemical compound
Nº Q424965 ★★★
Serotonin antagonist and reuptake inhibitor
Class of drugs
Nº Q7455057 ★
Catecholamine
4-(2-aminoethyl)pyrocatechol and derivatives formed by substitution
Nº Q271663 ★★★
Resiniferatoxin
Chemical compound
Nº Q3277888 ★★★